Explore our list of non-proprietary assays
Please contact us with any questions or if your compound is not on this list.
| Compound(s) | Species Matrix | Validated Range | Anticoagulant (s) |
|---|---|---|---|
| Abacavir | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
| Abiraterone | Human Plasma | 0.200–200 ng/mL | K2EDTA |
| Acetaminophen | Human Dried Blood Spot | 50.0–30,000 ng/mL | Sodium Heparin |
| Acetaminophen | Human Plasma | 50.0–30,000 ng/mL | Sodium Heparin |
| Acetaminophen | Human Urine | 1.00–250 µg/mL | NA |
| Albuterol | Human Plasma | 1.00–1,000 pg/mL | K2EDTA |
| Amprenavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA /K3EDTA |
| Apixiban | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
| Aripiprazole | Human Plasma | 1.00 - 1,000 ng/mL | K3EDTA |
| Atazanavir | Human Plasma | 1.00–1,000 ng/mL | K3EDTA |
| Atazanavir | Human Plasma | 10.0–5,000 ng/mL | K2/K3EDTA |
| Atazanavir | Human Plasma | 25.0–5,000 ng/mL | K2EDTA |
| Atazanavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| ATRIPLA™ (Tenofovir, Emtricitabine, Efavirenz) | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Bortezomib | Human Plasma | 0.500–500 ng/mL | Sodium Heparin |
| Budesonide | Human Plasma | 3.00–300 pg/mL | EDTA |
| Budesonide | Human Plasma | 10.0–5,000 pg/mL | K2EDTA |
| Buprenorphine | Human Plasma | 25.0–10,000 pg/mL | K2EDTA |
| Buprenorphine | Human Plasma | 0.0500–20.0 ng/mL | K3EDTA |
| Bupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Bupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Bupropion, Hydroxybupropion | Human Plasma | 0.0500–2,500 ng/mL | K2EDTA |
| Bupropion/ Hydroxybupropion/ Erythrohydrobupropion / Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | Sodium Heparin |
| Capecitabine | Human Plasma | 10.0–1,000 ng/mL | K2EDTA |
| Capsaicin | Human Plasma | 0.0500–50.0 ng/mL | K2EDTA |
| Clarithromycin | Human Plasma | 5.00 - 5,000 ng/mL | K3EDTA |
| Clindamycin | Human Plasma | 50–50,000 ng/mL | K2EDTA |
| Cortisol | Human Urine | 1.00 to 100 ng/mL | NA |
| Cortisol / 6beta-hydroxycortisol | Human Urine | 1.00–400 ng/mL for Cortisol 2.50–1,000 ng/mL for 6beta-hydroxycortisol | NA |
| Cyclophosphamide | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
| Cyclosporin A | Human Whole Blood | 5.00–2,000 ng/mL | K2EDTA /K3EDTA |
| Cyclosrporine | Human Whole Blood | 2.00–2,000 ng/mL | K2EDTA |
| Darunavir | Human Plasma | 20.0–4,000 ng/mL | K2EDTA |
| Darunavir | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| Dexamethasone | Human Plasma | 0.250–250 ng/mL | K2EDTA |
| Dextromethorphan | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Dextromethorphan | Human Urine | 1.00–500 ng/mL | NA |
| Dextromethorphan | Human Urine | 1.00–500 ng/mL | NA |
| Dextrorphan | Human Urine | 50.0–25,000 ng/mL | NA |
| Dextrorphan | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Dextrorphan | Human Urine | 1.00–500 ng/mL | NA |
| Diclofenac | Human Plasma | 0.100–100 ng/mL | NaHep |
| Diclofenac | Human Plasma | 10.00–2,000 ng/mL | K2EDTA |
| Digoxin | Human Plasma | 100–50,000 pg/mL | K2EDTA |
| Digoxin | Human Urine | 1.00–100 ng/mL | NA |
| Docetaxel | Human Plasma | 10.0–10,000 ng/mL | K2EDTA /K3EDTA |
| Doxorubicin | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
| Doxorubicin / Doxorubicinol | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Doxorubicinol | Human Plasma | 2.00–400 ng/mL | K2EDTA |
| Efavirenz | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
| Efavirenz | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Emtricitabine | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Emtricitabine | Human Plasma | 5.00–3,000 ng/mL | K2EDTA |
| Entecavir | Human Plasma | 0.0400–16.0 ng/mL | K2EDTA |
| Erythrohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Erythrohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Esomeprazole | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Eszopiclone | Human Plasma | 1.00–100 ng/mL | K3EDTA |
| Etravirine | Human Plasma | 2.00–400 ng/mL | K2EDTA |
| Everolimus | Human Whole Blood | 0.200–50.0 ng/mL | K2EDTA |
| Famotidine | Human Plasma | 1.00–500 ng/mL | K3EDTA |
| Famotidine | Human Plasma | 1.00–500 ng/mL | K3EDTA |
| Fluconazole | Human Plasma | 100–10,000 ng/mL | K3EDTA |
| Fluconazole | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
| Fluoxetine | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
| Fluticasone propionate | Human Plasma | 5.00–1,000 pg/mL or 5.00–500 pg/mL | K3EDTA |
| Fluticasone propionate | Human Plasma | 1.00–200 pg/mL | K2EDTA |
| Fluticasone propionate | Human Plasma | 3.00–300 pg/mL | K2EDTA |
| Formoterol | Human Plasma | 1.00–100 pg/mL | EDTA |
| Formoterol | Human Plasma | 1.00–100 pg/mL | K3EDTA |
| Furosemide | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| Gemfibrozil | Human Plasma | 50.0 - 25,000 ng/mL | Sodium Heparin |
| Guanfacine | Human Plasma | 0.0500–5.00 ng/mL | K2EDTA |
| Hydrochlorothiazide | Human Plasma | 1.00–200 ng/mL | K2EDTA |
| Hydroxybupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Hydroxybupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Ibandronate | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
| Ibandronate | Human Plasma | 0.200–200 ng/mL | K2EDTA |
| Iohexol | Human Plasma | 1.00–500 μg/mL | K2 EDTA |
| Iohexol | Human Urine | 2.00–1,000 μg/mL | NA |
| Irinotecan / SN-38 | Human Plasma | 5.00–2,500 ng/mL for Irinotecan and 1.00–500 ng/mL for SN-38 | K2EDTA |
| Itraconazole | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Itraconazole / Hydroxy Itraconazole | Human Plasma | 2.00–1,000 ng/mL | K2EDTA |
| Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | Sodium Heparin |
| Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | K2EDTA |
| Ketoconazole | Human Plasma | 50.0–5,000 ng/mL | K2EDTA |
| Ketoconazole | Human Plasma | 20.0–10,000 ng/mL | K2EDTA |
| Lamivudine | Human Plasma | 10.0–2,000 ng/mL | K2EDTA |
| Lenalidomide | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Lopinavir | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
| Losartan / Losartan Carboxylic Acid | Human Plasma | 1.00–1,500 ng/mL | K2EDTA |
| LTE4 | Human Urine | 2.00–500 pg/mL | NA |
| Maraviroc | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Mefenamic acid | Human Plasma | 50.0–5,000 ng/mL | K3EDTA |
| Memantine | Human Plasma | 0.100–100 ng/mL | K3EDTA |
| Mesalamine | MeCN Ext from HuP | 2.00–2,000 ng/mL | K2EDTA |
| Methadone/EDDP | Human Plasma | 0.200–400 ng/mL | K2EDTA |
| Methadone/EDDP | Human Urine | 0.200–400 ng/mL | NA |
| Methotrexate | Human Plasma | 1.00–500 ng/mL | NaEDTA |
| Methotrexate / 7-Hydroxymethotrexate | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Methotrexate / 7-Hydroxymethotrexate | Human Urine | 1,000–50,000 ng/mL / 50.0–2,500 ng/mL | NA |
| Methyl-Prednisolone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.200–10.0 ng/mL | EDTA/Lithium Heparin |
| Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.100–10.0 ng/mL | Na2EDTA |
| Midazolam / 1-Hydroxymidazolam | Human Plasma | 0.200–10.0 ng/mL | K2EDTA |
| Midazolam and Fexofenadine | Human Plasma | 0.100–300 ng/mL 2.00–6,000 ng/mL | K2EDTA |
| Midazolam and α-Hydroxymidazolam | Human Plasma | 0.100–100 ng/mL | K2EDTA |
| Moexipril | Human Plasma | 1.00–200 ng/mL | K2EDTA |
| Montelukast and Montelukast 1,2-diol | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
| Morphine | Human Plasma | 0.500–100 ng/mL | K2EDTA |
| Morphine / Morphine-3β-D-glucuronide / Morphine-6β-D-glucuronide | Human Plasma | 0.500–50.0 ng/mL / 10.0–1,000 ng/mL / 1.00–100 ng/mL | K2EDTA |
| Morphine-6-β-D-glucuronide | Human Plasma | 2.50–500 ng/mL | K2EDTA |
| Moxifloxacin | Human Plasma | 25.0–5,000 ng/mL | K2EDTA |
| Moxifloxacin | Human Plasma | 25.0–5,000 ng/mL | NaHep |
| Moxifloxacin | Human Plasma | 25.0–5000 ng/mL | Sodium Heparin |
| Mycophenolic acid | Human Plasma | 2.50–2500 ng/mL | K2EDTA |
| Mycophenolic acid-β-D-Glucuronide | Human Plasma | 25.0–25,000 ng/mL | K2EDTA |
| Naloxone | Human Plasma | 0.00500–2.00 ng/mL | K3EDTA |
| Naltrexone / Naltrexol | Human Plasma | 0.0200–2.00 ng/mL / 0.500–50.0 ng/mL | K2EDTA |
| Nelfinavir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA /K3EDTA |
| Nevirapine | Human Plasma | 20.0–4,000 ng/mL | K2EDTA |
| Nifedipine | Human Plasma | 1.00–250 ng/mL | K2EDTA |
| Nilotinib | Human Plasma | 5.00–2,000 ng/mL | K2EDTA |
| Nisoldipine | Human Plasma | 50.0–10,000 pg/mL | K2EDTA |
| Norbuprenorphine | Human Plasma | 50.0–20,000 pg/mL | K2EDTA |
| Norbuprenorphine | Human Plasma | 0.100–40.0 ng/mL | K3EDTA |
| Norethindrone/Ethinyl Estradiol | Human Plasma | 50.0–15,000 pg/mL 5.00–1,500 pg/mL | K2EDTA |
| Norfluoxetine aka Seproxetine | Human Plasma | 0.100–50.0 ng/mL | K2EDTA |
| Octreotide | Human Plasma | 0.0500–20.0 ng/mL | K2EDTA |
| Olanzapine | Human Plasma | 0.250–100 ng/mL | K2EDTA |
| Omeprazole | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Omeprazole / 5-Hydroxy Omeprazole | Human Plasma | 10.0–1,000 ng/mL | K2EDTA /K3EDTA |
| Paclitaxel | Human Plasma | 10.0–2,000 ng/mL | K3EDTA |
| Pramipexole | Human Plasma | 50.0–5,000 pg/mL | K3EDTA |
| Pramipexole | Human Plasma | 25.0–2,500 pg/mL | K2EDTA /K3EDTA |
| Prednisone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Pregabalin | Human Plasma | 50.0–20,000 ng/mL | K2EDTA |
| Prenisolone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| R,S-Methadone | Human Plasma | 0.500–100 ng/mL | K3EDTA |
| R,S-Methadone | Human Plasma | 5.00–1,000 ng/mL | K2EDTA /K3EDTA |
| Raltegravir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Raltegravir | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Raltegravir II | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| Ramelteon | Human Plasma | 0.0500–8.00 ng/mL | K2EDTA |
| Ribavirin | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Rifampin | Human Plasma | 50.0–35,000 ng/mL | K2EDTA and Sodium Fluoride/Potassium Oxalate |
| Rifampin | Human Plasma | 100–10,000 ng/mL | K2EDTA |
| Rifaximin | Human Plasma | 0.100–10.0 ng/mL | K2EDTA |
| Rilpivirine | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Riluzole | Human Dried Blood Spot | 5.00–2,000 ng/mL | K2EDTA |
| Riluzole | Human Plasma | 5.00–2,000 ng/mL | K2EDTA /K3EDTA |
| Risperidone / 9-Hydroxyrisperidone | Human Plasma | 0.200–100 ng/mL | K2EDTA |
| Ritonavir | Human Plasma | 1.00–1,000 ng/mL | K3EDTA |
| Ritonavir | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
| Ritonavir | Human Plasma | 10.0–5,000 ng/mL | K2EDTA /K3EDTA |
| Rosiglitazone | Human Plasma | 1.00–1,000 ng/mL | K2EDTA /K3EDTA |
| Rosuvastatin | Human Plasma | 0.100–100 ng/mL | K2EDTA |
| Rosuvastatin / Desmethyl Rosuvastatin / Rosuvastatin Lactone | Human Plasma | 0.0200–20.0 ng/mL for Rosuvastatin 0.100–10.0 ng/mL for Desmethyl Rosuvastatin 0.0500–10.0 ng/mL for Rosuvastatin Lactone | K2EDTA |
| R-Warfarin | Human Plasma | 10.0–2,500 ng/mL | K2EDTA |
| Salmeterol | Human Plasma | 2.50–500 pg/mL | K3EDTA |
| Salmeterol | Human Plasma | 1.00–100 pg/mL | K2EDTA |
| Salmeterol | Human Plasma | 1.00–200 pg/mL | K2EDTA |
| Saquinavir | Human Plasma | 2.00–400 ng/mL | K2EDTA |
| Scopolamine | Human Plasma | 0.00200–2.00 ng/mL | K2EDTA |
| Sertraline / N-desmethylsertraline | Human Plasma | 0.250–100 ng/mL for Sertraline 0.500–100 ng/mL for N-desmethylsertraline | Sodium Heparin |
| Sildenafil and N-desmethyl sildenafil | Human Plasma | 0.500–500 ng/mL | K2EDTA |
| Stavudine | Human Plasma | 5.00–1,000 ng/mL | K2EDTA |
| S-Warfarin | Human Plasma | 10.0–2,500 ng/mL | K2EDTA |
| Tacrolimus | Human Whole Blood | 50.0–10,000 pg/mL | K2EDTA |
| Tacrolimus | Whole Blood | 0.100–100 ng/mL | K2EDTA |
| Tadalafil | Human Plasma | 1.00–500 ng/mL | K3EDTA |
| Telmisartan | Human Plasma | 0.500–5,000 ng/mL | K3EDTA |
| Temozolomide | Human Plasma | 100–20,000 ng/mL | K2EDTA |
| Tenofovir | Human Plasma | 5.00–3,000 ng/mL | K2EDTA |
| Tenofovir | Human Plasma | 1.00–500 ng/mL | K2EDTA /K3EDTA |
| Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Threohydrobupropion | Human Plasma | 1.00–1,000 ng/mL | K2EDTA |
| Tiotropium | Human Plasma | 1.00–500 pg/mL | K2EDTA |
| Tiotropium | Human Plasma | 0.500–500 pg/mL | K2EDTA |
| Tolbutamide / 4-hydroxytolbutamide | Human Plasma | 5.00–5,000 ng/mL | K2EDTA |
| Total 4-beta hydroxycholesterol | Human Plasma | 4.00–400 ng/mL | K2EDTA |
| Total cholesterol | Human Plasma | 500–5,000 μg/mL | K2EDTA |
| Tramadol | Human Plasma | 1.00–500 ng/mL | K2EDTA |
| Valproic acid | Human Plasma | 0.200–100 μg/mL | K2EDTA |
| Valproic Acid aka valproate | Human Serum | 1–100 μg/mL | NA |
| Valsartan | Human Plasma | 50.0–10,000 ng/mL | K2EDTA /K3EDTA |
| Vardenafil | Human Plasma | 0.200–50.0 ng/mL | K2EDTA /K3EDTA |
| Vincristine | Human Plasma | 0.500–100 ng/mL | K2EDTA |
| Voriconazole | Human Plasma | 5.00–5,000 ng/mL | K2EDTA /K3EDTA |
| Warfarin (R-) / Warfarin (S-) | Human Plasma | 10.0–1,000 ng/mL | K3EDTA |
| Zidovudine | Human Plasma | 4.00–800 ng/mL | K2EDTA |
| 4-beta Hydroxycholesterol | Human Plasma | 4.00–400 ng/mL | K2EDTA |
| Atorvastatin, para-Hydroxy Atorvastatin and ortho-Hydroxy Atorvastatin | Human Plasma | 0.300–50.0 ng/mL | K2EDTA |
| Aldosterone | Human Plasma | 10.0–5,000 pg/mL | K2EDTA |
| Aldosterone | Human Urine | 0.200–200 ng/mL | K2EDTA |
| Bile Acids (11 acids) | Human Plasma | 2.00–1,000 ng/mL/ 1.00–500 ng/mL/ 5.00–2,500 ng/mL | K2EDTA |
| Salicylic Acid and Acetylsalicylic Acid | Human Plasma | 25.0–25,000 ng/mL | Sodium Fluoride/Potassium Oxalate |
| Thromboxane B2 | Human Serum | 1.00–500 ng/mL | NA |
| Total Dabigatran | Human Plasma | 1.10–550 ng/mL | K2EDTA |
| Dabigatran | Human Plasma | 1.10–550 ng/mL | K2EDTA |
| Irbesartan | Human Plasma | 10.0–10,000 ng/mL | K2EDTA |
| Letrozole | Human Plasma | 0.500–250 ng/mL | K2EDTA |